Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole versus placebo in adults with borderline personality disorder
2019-002813-20Phase 2Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in borderline personality disorder (BPD) comparing Brexpiprazole with Placebo (2 arms). Primary endpoint: Change from baseline in Zanarini Rating Scale for Borderline Personality Disorder total score. Started Nov 2019; status: terminated.
02
Drugs
brexpiprazole
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on 2019-002813-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002813-20.